Scope of our work


The scope of the Cochrane Heart Group includes primary prevention, acute treatment, secondary prevention and rehabilitation, in all forms of heart disease, including ischaemic heart disease, heart diseases more common in developing countries, arrhythmias, valvular and congenital heart diseases.

The Cochrane Heart Group reviews predominantly draw on sources of evidence from randomised controlled trials (RCTs). Occasionally, RCTs of quasi-experimental designs are used in topics concerned with public health policy and practice where RCTs are inappropriate tests of the efficacy of community level interventions.

Our priority for accepting reviews are:

  • the review covers heart disease where the disease burden is considerable, i.e affects many people, 
  • disease types or interventions with special reference to heart disease in low income countries, for example rheumatic fever, Chagas disease and Brughada syndrome,  
  • reviews on topics which are not the topic of current or recent good quality systematic reviews available in the public domain. For example a topic recently systematically reviewed by AHRQ or the HTA UK for example.


You can support the Cochrane Heart Group if you want to...

  • Prepare and maintain a systematic review
  • Volunteer as member of the Editorial Team
  • Suggest topics requiring review.
  • Help us start undertaking reviews of diagnostic methods in heart disease.
  • Promote awareness and understanding of the value of systematic reviews .
  • Help reviewers identify unpublished data and additional information about  trials.
  • Provide members of the Cochrane Heart Group with methodological advice and support.

In particular, people living with heart disease can help us provide a patient perspective on our  reviews.


Reviews that need new review teams:

We have reviews which require completing or updating because the original review team is unable to so. If you are keen establish a new team and would like to pursue this, please contact us. The reviews in question are: 

Review which requires updating:

  • Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes